Identification of the first cases of complete CD16A deficiency: Association with persistent EBV infection - 06/04/20
Doi : 10.1016/j.jaci.2019.11.049
A. Pérez-Portilla, BSc, PhD a, ∗, M. Moraru, MD, PhD b, Alfonso Blázquez-Moreno, BSc, PhD a, Philipp Kolb, PhD c, María Bravo García-Morato, BSc, PhD d, Thanmayi Ranganath, BSc, MSc e, Gloria Esteso, BSc, PhD a, Carla Gianelli, MD d, Rebeca Rodríguez-Pena, MD, PhD d, Roberto Lozano-Rodríguez, BSc a, Juan Manuel Torres-Canizales, MD d, Catherine A. Blish, MD, PhD e, Mar Vales-Gomez, BSc, PhD a, Hartmut Hengel, PhD c, Carlos Vilches, MD, PhD b 
, Eduardo López-Granados, MD, PhD d , Hugh T. Reyburn, BVMS, MRCVS, PhD a
, Eduardo López-Granados, MD, PhD d , Hugh T. Reyburn, BVMS, MRCVS, PhD a a Department of Immunology and Oncology, National Centre for Biotechnology (CNB-CSIC), Madrid, Spain
b Department of Immunology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
c Institute of Virology, Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany
d Clinical Immunology Department, University Hospital La Paz and Lymphocyte Pathophysiology in Immunodeficiencies Group, IdiPAZ Institute for Health Research, Madrid, Spain
e Department of Medicine, Stanford University School of Medicine, Stanford, Calif
| This work was supported by grants SAF2014-58752-R and SAF2017-83265-R to H.T.R. and grant SAF2016-80363-C2-2-R to C.V. (Spanish Science agency/European Regional Development Fund, European Union, AEI/FEDER, EU). The group of M.V.-G. has also received funding from the Spanish Ministry of Science and Innovation (grant nos. RTC-2017-6379-1 and RTI2018-093569-B-I00 [MCIU/AEI/FEDER, EU]) and the regional government of Madrid (grant no. S2017/BMD-3733-2). The group of M.V.-G. also belongs to the research network TENTACLES (RED2018-102411-T) funded by the Spanish Ministry of Science. A.P.P. and A.B.M. acknowledge PhD studentships funded by the National Secretary of Higher Education, Science, Technology and Innovation (SENESCYT, Ecuador) and Spanish Ministry of Economy and Competitivity (MINECO), respectively (SVP-2014-068263). M.M. was supported by grant GCB15152947MELE from Fundación de la Asociación Española contra el Cáncer. Work in the laboratory of H.H. is supported by Infect-ERA grant TANKACY, BMBF 031L0090, and German Research Foundation (DFG) grant HE2526/9-1. E.L.G. has grants from the Spanish Association Against Cancer (AECC) and Carlos III Health Institute (grant no. PI16/01605). C.A.B. acknowledges support from the National Institutes of Health (grant no. DP2AI11219301). The agencies who provided financial support for the conduct of the research and preparation of the article played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Reservados todos los derechos.
Vol 145 - N° 4
P. 1288-1292 - avril 2020 Regresar al número
Artículo precedente
- Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients
- Jacob W. Glickman, Celina Dubin, Joseph Han, Dante Dahabreh, Sandra Garcet, James G. Krueger, Ana B. Pavel, Emma Guttman-Yassky
- A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol
- Edwin H. Kim, Stacie M. Jones, A. Wesley Burks, Robert A. Wood, Scott H. Sicherer, Donald Y.M. Leung, Alice K. Henning, Robert W. Lindblad, Peter Dawson, Corinne Keet, Amy M. Scurlock, Marshall Plaut, Hugh A. Sampson
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?